Document is current
Any future updates will be listed below
-
Authors
Mohyuddin, Ghulam Rehman https://orcid.org/0000-0001-6464-783X
Chakraborty, Rajshekhar
Calip, Gregory S. https://orcid.org/0000-0002-7744-3518
Ascha, Mustafa S.
Wang, Xiaoliang
Rubinstein, Samuel M.
Tuchman, Sascha https://orcid.org/0000-0003-2109-1573
Costa, Luciano https://orcid.org/0000-0001-5362-2469
Haaland, Benjamin
Giri, Smith
Mian, Hira https://orcid.org/0000-0003-1584-1067
Fonseca, Rafael https://orcid.org/0000-0002-5938-3769
Sborov, Douglas https://orcid.org/0000-0003-4268-2698
- License Information
-
More Information
Article History
Received: 6 October 2022
Revised: 30 November 2022
Accepted: 5 December 2022
First Online: 16 December 2022
Competing interests
: SMR reports consulting with Janssen, Sanofi, Roche Diagnostics, and EUSA Pharma. LC reports consulting with BMS, Janssen, Amgen, Sanofi, Adaptive, and research support from Janssen, BMS, Amgen. DS reports consulting for Janssen, SkylinDx, GlaxoSmithKline, Legend Biotech, Amgen and Celgene. RC reports consulting with Janssen and Sanofi. HM reports consulting with Amgen, GlaxoSmithKline, Janssen, Sanofi, Takeda. HM is the recipient of an early career research award from Hamilton Health Sciences Foundation. HM also reports research support from Janssen. SG reports honoraria from Caelum, Oncopeptides, Sanofi, CareVive, OncLive, Research Support from Carevive Systems, Pack Health and Janssen and research funding from Karyopharm, Sanofi, and Caelum. GSC, MSA, and XW report current employment with Flatiron Health and stock ownership in Roche. GRM has no conflict of interest to declare.
